Signatera Residual Disease Testing Services
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This subcontract involves the provision of proprietary molecular genetic reference testing for prime contractors supporting Department of Veterans Affairs VISN 17 projects. The scope of work focuses on the execution of Signatera Residual Disease Tests and non-liquid biopsy tumor typing, utilizing specialized bioinformatics platforms, assays, and reagents. These services are specifically designed for cancer residual disease monitoring and must adhere to CPT Codes 81479 and 81455. Managed under NAICS code 621511, the contract requires the delivery of comprehensive molecular test results and detailed reports. The project is overseen by the Department of Veterans Affairs Network Contract Office 17, with a response deadline set for October 30, 2026.
General Info
Place of Performance
TXSet-Aside
Documents
This scope was carved out of 36C25727Q0058.
The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.
Q301--NEW – STX Specialized Molecular Residual Disease Testing
AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
